Koffiekamer « Terug naar discussie overzicht

Aptevo therapeutics

78 Posts, Pagina: 1 2 3 4 » | Laatste
ThierryD
0
Vrijdag vreemd dagje voor dit aandeel. Hoewel ik er geen info over terugvind
Et een onderliggende reden. Iemand een idee/feedback?
MisterBlues
0
Het aandeel is omhoog geschoten, > 500%. Waarom?

Op het Yahoo forum schreef iemand dit ca. een maand geleden:

"We can't change the world, but we can change the subject" ? James Joyce, Ulysses
It seems possible that in the near future this could become a fair trading area in $12,5.
To assess this area, it is enough to understand that, already in the immediate future, the importance and usefulness of influencing social society in the world, the ADAPTIR platform will appear as a security product to protect and strengthen human immunity.
Development of ADAPTIR constructs is a unique approach to the treatment of cancer and hematological disorders, autoimmune and other diseases of the immune system, and what is most important and relevant during today's dramatic events, and possibly new, hypothetical attacks in the ongoing future human world, are infectious diseases.It is important to understand the essence that, without an immune system, a person is susceptible to any virus attack, and in the first place, the Adaptir platform is proven to receive an answer in improving the human immune system to such pandemics.
Today, the company is actively seeking opportunities to develop new bispecific #ADAPTIR molecules with pharmaceutical partners. And I would not be surprised if the company has already sent a request to evaluate future partnerships to such companies as Merck, Roche, Pfizer.
pardon
0
Vrijdag al 205 HOGER EN NU 24% HOGER IEMAND EEN IDEE WAAROM DEZE STIJGING VAN DE KOERS??
MisterBlues
0
Dit is het laatste bericht dat ik vond na een eerste zoektocht.

SEATTLE, WA / ACCESSWIRE / April 14, 2020 / Aptevo Therapeutics Inc. (APVO), a biotechnology company focused on developing novel immuno-oncology therapeutics based on its proprietary ADAPTIR™ bispecific technology platform, today announced that it has received notice from The NASDAQ Stock Market LLC (NASDAQ) on April 13, 2020 informing Aptevo that it has regained compliance with the minimum bid price requirement under NASDAQ Listing Rule 5550(a)(2) for continued listing on The NASDAQ Capital Market. Consequently, Aptevo is now in compliance with all applicable listing standards and its common stock will continue to be listed on The NASDAQ Capital Market.

Aptevo was previously notified by NASDAQ on April 18, 2019 that it was not in compliance with the minimum bid price rule because its common stock failed to meet the closing bid price of $1.00 or more for 30 consecutive business days. In order to regain compliance with the Rule, the Company was required to maintain a minimum closing bid price of $1.00 or more for at least 10 consecutive trading days. This requirement was met on April 9, 2020, the tenth consecutive trading day when the closing bid price of the Company's common stock was over $1.00.

About Aptevo Therapeutics Inc.

Aptevo Therapeutics Inc. is a clinical-stage biotechnology company focused on developing novel immunotherapies for the treatment of cancer. The Company's lead clinical candidate, APVO436, and preclinical candidates, ALG.APV-527 and APVO603 were developed based on the Company's versatile and robust ADAPTIR™ modular protein technology platform. The ADAPTIR platform is capable of generating highly differentiated bispecific antibodies with unique mechanisms of action for the treatment of different types of cancer. For more information, please visit www.aptevotherapeutics.com

Safe Harbor Statement

This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements, other than statements of historical fact, including, without limitation, statements regarding potential milestone payments, Aptevo's outlook, financial performance or financial condition, Aptevo's technology and related pipeline, collaboration and partnership opportunities, commercial portfolio, milestones, and any other statements containing the words "believes," "expects," "anticipates," "intends," "plans," "forecasts," "estimates," "will" and similar expressions are forward-looking statements. These forward-looking statements are based on Aptevo's current intentions, beliefs and expectations regarding future events. Aptevo cannot guarantee that any forward-looking statement will be accurate. Investors should realize that if underlying assumptions prove inaccurate or unknown risks or uncertainties materialize, actual results could differ materially from Aptevo's expectations. Investors are, therefore, cautioned not to place undue reliance on any forward-looking statement. Any forward-looking statement speaks only as of the date of this press release, and, except as required by law, Aptevo does not undertake to update any forward-looking statement to reflect new information, events or circumstances.

There are a number of important factors that could cause Aptevo's actual results to differ materially from those indicated by such forward-looking statements, including a deterioration in Aptevo's business or prospects; adverse developments in research and development; adverse developments in the U.S. or global capital markets, credit markets or economies generally; and changes in regulatory, social and political conditions. Additional risks and factors that may affect results are set forth in Aptevo's filings with the Securities and Exchange Commission, including its most recent Annual Report on Form 10-K, as filed on March 25, 2020 and its subsequent reports on Form 10-Q and current reports on Form 8-K. The foregoing sets forth many, but not all, of the factors that could cause actual results to differ from Aptevo's expectations in any forward-looking statement.

CONTACT:

Aptevo Therapeutics
Stacey Jurchison
Senior Director, Investor Relations and Corporate Communications
206-859-6628
JurchisonS@apvo.com

SOURCE: Aptevo Therapeutics
MisterBlues
0
De biotech had een ipo rond de 35 dollar en stond 2 jaar terug op ca 80 dollar.

Er is dus een opleving van het vertrouwen in deze immuno-oncologie specialist met hun ADAPTIR™ bispecific technology platform.

Weet jij meer @ pardon?
pardon
0
Nee ik kan ook niets vinden, maar sta op een leuke winst en verkoop niet je weet niet wat je kunt verwachten kan alle kanten op.
MisterBlues
0

ADAPTIR™ Platform Overview

Our development focus centers around our proprietary ADAPTIR platform, a novel approach for the generation of immunotherapeutics.

The highly versatile ADAPTIR platform holds great promise for product candidate generation, target validation, and clinical development.

We are applying ADAPTIR technology to develop immuno-oncology candidates that focus on redirected T-cell cytotoxicity (RTCC). ADAPTIR technology is modular and can be used to generate immunotherapeutics with unique mechanisms of action including targeted cytokine delivery, targeting two cell surface receptors or neutralization of multiple soluble proteins.

ADAPTIR redirected T-cell candidates hold distinct advantages over other immunotherapeutic and bispecific T-cell technologies.

In pre-clinical studies, ADAPTIR candidates have been shown to possess superior properties:

High potency; ADAPTIR bispecific proteins induce target-dependent cytotoxicity at low concentrations
Extended serum half-life that enables less frequent administration
Reliable antibody-like manufacturing processes

The ADAPTIR platform offers a great opportunity for use in combination with other immunotherapeutics and can also be configured to produce other types of multispecifics.

Aptevo Therapeutics and the ADAPTIR™ (Modular Protein Technology) Platform: The Future of Immuno-oncology

Aptevo Therapeutics Inc. is a clinical-stage biotechnology company focused on developing novel oncology and hematology therapeutics to meaningfully improve patients’ lives. Aptevo has a commercial product, IXINITY® coagulation factor IX (recombinant), approved and marketed in the United States for the treatment of Hemophilia B, and a versatile core technology – the ADAPTIR™ modular protein technology platform capable of generating highly-differentiated bispecific antibodies with unique mechanisms of action to treat cancer and autoimmune diseases.

MisterBlues
0
Zij hebben – gezien hun pijplijn - 4 kandidaat-medicijnen/behandelingen die allemaal gebaseerd zijn op de technologie van hun platform Adaptir, RTCC – Redirected T-Cell Cytotoxicity = T-Cell Engager. Slechts 1 daarvan is in fase 1, de overige 3 zijn nog in de pre-klinische fase.

Het doet me een beetje denken aan Arrowhead met zijn RNAi platform in 2019. Alle verwachtingswaarde daarvan werd gebaseerd op de nieuwe technologie van het platform. Het idee was dat als de technologie werkt dan kan je daar talloze medicijnen mee ontwikkelen. Toch bleek de praktijk veel weerbarstiger te zijn. Het aandeel is wel gegroeid van 1,5 naar 45! En nu hangt het een beetje.

Ik denk dat we maar het beste kunnen gaan naar het yahoo/forum voor de zienswijze van beleggers op het aandeel Aptevo Pharmaceutics.

Of @ pardon, beleg jij enkel op de goede gok?
MisterBlues
0
Dit is wat ik bedoel met eerdere toepassingen van het platform / technologie:

Multiple Candidates

Aptevo Therapeutics is committed to building a robust pipeline of preclinical ADAPTIR™ bispecific candidates with a focus on novel mechanisms of action. By leveraging our proprietary ADAPTIR platform, these new candidates utilize multiple mechanisms of action, including redirected T-cell cytotoxicity (RTCC), T-cell co-stimulators, and targeted cytokine delivery to exploit new biological pathways for the discovery and development of novel cancer and autoimmune therapies.
MisterBlues
0
Partner van Aptevo is het in Zweden gelokaliseerde
Alligator Bioscience

Alligator develops antibody-based pharmaceuticals for cancer treatment. The company specializes in the development of tumor-directed immunotherapies, in particular agonistic mono- and bispecific antibodies. The company is active in the early stages of drug development, from idea to clinical phase II studies.

ALG.APV.527 kandidaat-medicijn tegen meerdere solide kankers wordt gemeenschappelijk ontwikkeld met Aptevo en zit nog in de klinische fase.

Aandeel ALLIGATOR BIOSCIENCE AB CHX:ATORX, SE0000767188
MisterBlues
0
Totaal onbegrijpelijk aandeel: binnen 1 week stijging van 35% en nu binnen een uur na opening beurs al 20% eraf. Er is geen Covid-19 programma; überhaupt geen nieuws, geen bedrijfs- PB, geen concurrent die iets beters heeft etc. etc.

MisterBlues
0
quote:

Lego schreef op 11 oktober 2020 19:35:

Is er nog iemand die dit aandeel volgt ?
Jij?
[verwijderd]
0
quote:

MisterBlues schreef op 12 oktober 2020 09:46:

[...]

Jij?
Ik ben het aandeel nog maar recent aan het volgen na een tip hier op het forum.
Laatste nieuws van 1 september was dat de ontwikkeling van hun APVO436 middel "op schema" ligt.

MisterBlues
0
quote:

Lego schreef op 14 oktober 2020 19:33:

[...]

Ik ben het aandeel nog maar recent aan het volgen na een tip hier op het forum.
Laatste nieuws van 1 september was dat de ontwikkeling van hun APVO436 middel "op schema" ligt.

Ik hoop dat je het blijft volgen. Ik denk dat hier wel iets meer in het vat zit. Het gaat tenslotte om een uitgebreid bio-technologisch platform.

ADAPTIR™ Platform Overview

Our development focus centers around our proprietary ADAPTIR platform, a novel approach for the generation of immunotherapeutics.

The highly versatile ADAPTIR platform holds great promise for product candidate generation, target validation, and clinical development.

We are applying ADAPTIR technology to develop immuno-oncology candidates that focus on redirected T-cell cytotoxicity (RTCC). ADAPTIR technology is modular and can be used to generate immunotherapeutics with unique mechanisms of action including targeted cytokine delivery, targeting two cell surface receptors or neutralization of multiple soluble proteins.

ADAPTIR redirected T-cell candidates hold distinct advantages over other immunotherapeutic and bispecific T-cell technologies.

In pre-clinical studies, ADAPTIR candidates have been shown to possess superior properties:

High potency; ADAPTIR bispecific proteins induce target-dependent cytotoxicity at low concentrations
Extended serum half-life that enables less frequent administration
Reliable antibody-like manufacturing processes

The ADAPTIR platform offers a great opportunity for use in combination with other immunotherapeutics and can also be configured to produce other types of multispecifics.

Aptevo Therapeutics and the ADAPTIR™ (Modular Protein Technology) Platform: The Future of Immuno-oncology

Aptevo Therapeutics Inc. is a clinical-stage biotechnology company focused on developing novel oncology and hematology therapeutics to meaningfully improve patients’ lives. Aptevo has a commercial product, IXINITY® coagulation factor IX (recombinant), approved and marketed in the United States for the treatment of Hemophilia B, and a versatile core technology – the ADAPTIR™ modular protein technology platform capable of generating highly-differentiated bispecific antibodies with unique mechanisms of action to treat cancer and autoimmune diseases.
[verwijderd]
0
Ik ga het zeker blijven volgen. Voorlopig zonder aandelen te bezitten.
Verwacht je op een korte termijn terug een stijging ?
MisterBlues
0
quote:

Lego schreef op 16 oktober 2020 19:05:

Ik ga het zeker blijven volgen. Voorlopig zonder aandelen te bezitten.
Verwacht je op een korte termijn terug een stijging ?
Ik hoopte dat jij dat zou willen uitzoeken?

Ik kijk de kat uit de boom!
78 Posts, Pagina: 1 2 3 4 » | Laatste
Aantal posts per pagina:  20 50 100 | Omhoog ↑

Meedoen aan de discussie?

Word nu gratis lid of log in met uw e-mailadres en wachtwoord.

Direct naar Forum

Markt vandaag

 AEX
870,27  -3,75  -0,43%  18:05
 Germany40^ 17.939,20 -0,83%
 BEL 20 3.857,94 -0,67%
 Europe50^ 4.953,67 -0,73%
 US30^ 37.930,24 -1,10%
 Nasd100^ 17.435,30 -0,51%
 US500^ 5.046,94 -0,50%
 Japan225^ 37.475,14 -1,38%
 Gold spot 2.334,20 +0,78%
 EUR/USD 1,0727 +0,28%
 WTI 83,25 +0,42%
#/^ Index indications calculated real time, zie disclaimer

Stijgers

UNILEVER PLC +5,85%
RENEWI +4,68%
B&S Group SA +2,85%
Flow Traders +2,26%
Fugro +2,09%

Dalers

ADYEN NV -18,43%
VIVORYON THER... -8,38%
WDP -4,93%
Alfen N.V. -4,39%
CM.COM -3,66%

EU stocks, real time, by Cboe Europe Ltd.; Other, Euronext & US stocks by NYSE & Cboe BZX Exchange, 15 min. delayed
#/^ Index indications calculated real time, zie disclaimer, streaming powered by: Infront